AQP5 and chronic myelogenous leukemia, BCR-ABL1 positive: However, when AQP5 expression levels were compared between the paired bone marrow samples drawn before and after the emergence of imatinib mesylate resistance in the same CML patients (n = 9), a statistically significant difference was found (p = 0.047) (Table 2).